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Key Messages: 
 DACC-coated dressings are a relatively new addition to the wound care arsenal and 
act to bind and remove bacteria from the wound bed. 
 We undertook a systematic review of 17 articles to assess the current level of 
evidence to support the use of DACC coated dressings in routine clinical practice. 
 Current evidence is limited but promising, and further high quality studies are 
required to further investigate their clinical and cost effectiveness.  
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Abstract 
 
Introduction: Dialkylcarbomoylchloride (DACC) coated dressings irreversibly bind bacteria at 
the wound surface that are then removed when the dressing is changed. They are a recent 
addition to the wound care professionals’ armamentarium and have been used in a variety 
of acute and chronic wounds. This systematic review aims to assess the current evidence 
supporting the use of DACC coated dressings in the clinical environment.  
Methods: We included all reports of the clinical use of DACC coated dressings in relation to 
wound infection. Medline, Embase, CENTRAL and CINAHL databases were searched to 
September 2016 for studies evaluating the role of DACC-coated dressings in preventing or 
managing wound infections.  
Results: Seventeen studies with a total of 3408 patients were identified and included in this 
review. DACC coating was suggested to reduce post-operative infection rates and result in 
chronic wounds that subjectively looked cleaner and had less bacterial load on 
microbiological assessments.  
Conclusions: Existing evidence for DACC dressing in managing chronic wounds or as a 
surgical site infection prophylaxis is limited but encouraging with current evidence in 
support of DACC coated dressings preventing and treating infection without adverse effects.  
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Background 
Wound infections are a significant burden to both the individuals suffering the infected 
wound and to the healthcare systems treating them. The annual incidence of infected 
chronic wounds is up to 500,000 cases per year1 and the incidence of surgical site infections 
(SSI) is reported as between 5-20%2. Apart from the morbidity and social implications of 
living with a wound infection, the financial costs to the NHS are significant, with the costs of 
SSI alone estimated at £700 million per annum3 4. To date various antimicrobial wound 
dressings using silver, iodine or Polyhexamethylene biguanide have all been employed to try 
to reduce the microbial burden within wounds. Dialkylcarbomoylchloride (DACC) coated 
dressings are a recent addition to this group.  
DACC is a fatty acid derivative that is highly hydrophobic. Micro-organisms commonly 
responsible for causing SSI or colonising chronic wounds generally have hydrophobic extra-
cellular surfaces, and will therefore irreversibly adhere to the DACC coating on dressings5. 
Subsequent dressing changes will then result in the removal of large numbers of microbes 
and a decreased bacterial load at the wound site6. Mechanical removal of bacteria comes 
with several additional potential advantages; DACC coated dressings have shown no 
evidence of wound or systemic absorption of dressing component, or adverse reactions 
other than to the adhesive component of the dressing7. Perhaps most importantly, since the 
mechanism of antibacterial action is of physical binding and removal, there is no risk of 
bacteria developing resistance, and the lack of bacteriolysis prevents endotoxin release to 
the wound bed8. Leukomed® Sorbact®, an example of a DACC-coated dressing, is 
demonstrated in Figure 1. 
 
Objectives 
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The aim of this review is to assess the current available evidence supporting the clinical use 
of DACC coated dressings in managing or preventing wound infections. 
 
Methods 
Criteria for considering studies for this review 
All studies investigating the role of DACC coated dressings in wound care, with primary or 
secondary outcomes related to infection, were considered for inclusion, including both 
randomised and non-randomised trials, cohort studies and case series. Only full text reports 
regarding human subjects and in the English language were included. 
Studies were excluded if the report was regarding an in-vitro or basic science study 
exploring the mode of action of DACC coatings, if DACC was used in conjunction with other 
advanced dressing systems (such as negative pressure wound therapy), or the article was a 
case series with less than three cases. 
 
Search Strategy 
This systematic review was undertaken in line with recommendations from the PRISMA 
statement9. Medline, Embase, CENTRAL and CINAHL databases were searched from 1946 to 
September 2016. The full search strategy used is given in table 1. Additional articles were 
sourced by hand searching the reference lists of relevant articles and via a google scholar 
search.  
 
Selection of studies and data extraction 
Abstracts returned from the above search were assessed for inclusion by three authors 
acting independently (JT, NB, GS). If felt suitable for inclusion, the full text of the report was 
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obtained and further assessed against inclusion criteria by the same three authors. Any 
disagreement was resolved by consensus with input from a fourth author (AH). Study 
design, patient population, sample size, primary and secondary clinical outcomes and 
results or clinical impressions of the effects of DACC coated dressings were independently 
extracted by 3 investigators (JT, NB and GS) and collated using a structured data extraction 
table for analysis. 
 
Assessment of risk of bias in individual studies 
The Cochrane risk of bias tool10 and JADAD scoring system11 were used to assess 
methodological quality of randomised controlled trials (RCTs) and cohort studies included in 
this review. Two reviewers (NB and JT) assessed the risk of bias of included studies 
independently and collated results in an assessment of risk bias table.  
 
Results 
Results of the search and Included studies 
A PRISMA flow diagram is included (Figure 2) displaying the full results of searches. 252 
articles were identified by the search strategy outlined above. Of these 252, 34 were 
considered for inclusion after screening by title and abstract, and the full text sought. After 
full text reading, 17 were considered to be suitable for inclusion12-28 (Table 2). 
Suitable studies included four RCTs21 22 27 28, two cohort studies16 20 and eleven case series12-
15 17-19 23-26. 
In general, included studies fell into two types; those investigating DACC coated dressings in 
chronic wounds with or without signs of infection (One RCT22, two cohort studies16 20 and 
ten case series12 13 15 17-19 23-26, total 281 patients) and those investigating the use of DACC 
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coated dressings in the prevention of infection in clean surgical wounds (three RCTs21 27 28 
and one case series14, total 3133 patients). 
 
Excluded studies 
The full reasons for exclusion are shown in figure 2. 
 
Risk of Bias in included studies 
The Cochrane risk of bias tool for RCTs10 together with JADAD11 scores demonstrated 
moderate risk of bias in included studies (tables 3 and 4).  The cohort study by Kleintjes20 
was deemed to have a low risk of bias. Of the randomised trials, only the trial by Mosti et 
al22 had a JADAD score ≥3. Important sources of bias in the three randomised trials 
examining DACC for prevention of infection21 27 28 included a lack of true randomisation, 
with alternating sequence allocation used in all three trials, and a lack of allocation 
concealment and assessor blinding in trials. Of the three, only the 2016 study by 
Stanirowski27 attempted any form of blinding or concealment, with surgeons ‘blinded’ to 
the allocation of the patient until the point of dressing application (at which point they 
became aware of allocation due to the physical appearance of the test dressings). 
 
DACC coated dressings in chronic wound management 
The use of DACC coated dressings in chronically infected wounds was reported in one pilot 
RCT by Mosti et al22, two cohort studies by Kleintjes et al20 and Gentili et al16, and ten case 
series12 13 15 17-19 23-26.  
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Mosti et al22 performed a pilot RCT comparing the effects of DACC coated dressings and 
silver impregnated dressings in chronically infected or heavily colonised leg ulcers of 
vascular origin. The primary outcome measured was a reduction in bacterial load at day 4 of 
treatment. They found a reduction of bacterial load of 73.1% in the DACC cohort, compared 
to a reduction of 41.6% in the silver cohort, a statistically significant reduction (p<0.01). 
Although the difference in reduction of bacterial load between the two dressings was 
statistically significant, there is no comment regarding the clinical significance of this effect. 
 
Kleintjes et al20 published a cohort study of 13 patients with partial or full-thickness burn 
wounds, comparing DACC coated dressings with two branded silver impregnated dressings 
(Acticoat® and Silverlon®). Included wounds were large enough that 2 or 3 dressing types 
could be applied to different aspects of each wound. Though no statistically significant 
differences were seen between dressings, authors report that wounds appeared 
subjectively cleaner, and wound bacterial burden (based on bacterial cultures) was less in 
swabs from DACC coated dressing sites with 33% positive cultures, compared to the 37.5% 
in Acticoat and 44% in Silverlon dressing sites. 
 
Gentili et al16 examined a novel method of testing bacterial load in the context of a cohort 
study including 19 patients (20 wounds) with chronically infected vascular ulcers. All 
patients were treated for four weeks with Cutimed® Sorbact® (DACC coated) dressings 
changed twice weekly. Panbacterial real-time PCR was used to assess bacterial load at a 
wound site before and after a four-week treatment course with DACC coated dressings. 
Investigators reported that 10/15 (66%) had a positive outcome in relation to wound size 
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reduction and that these wounds also demonstrated a reduction in bacterial load measured 
using real-time PCR. 
 
Ten case series12 13 15 17-19 23-26 with a total of 209 patients reported mainly subjective results 
following the use of DACC dressings in chronically infected wounds, with a variety of 
primary and secondary outcomes including, but not limited to, exudate, erythema, odour, 
slough and pain. All authors felt that there was significant clinical improvement of the 
affected wounds (reduction in slough and exudate) seen with DACC coated dressings, but 
due to the nature of the studies, no quantifiable data could be extracted for synthesis from 
the studies for the purpose of this review. 
 
DACC coated dressings in the prevention of wound infection in clean surgical wounds 
Three RCTs21 27 28 and one case series14 examined the use of DACC coated dressings in clean 
surgical wounds.  
 
Stanirowski et al published both a pilot and a full RCT27 28 examining post-surgical wound 
dressing. Patients undergoing caesarean section were randomised to either DACC coated or 
standard dressings. The pilot study included 142 patients and the full trial 543 patients. 
Patients were followed up for 14 days and the presence of SSI was assessed using Centre for 
Disease Control criteria. In the pilot study the investigators reported a SSI rate of 2.8% in the 
DACC group compared to 9.8% in the standard dressing group (p = 0.08). This effect size 
informed the power calculation for the full RCT, which reported overall SSI rates of 1.8% 
with DACC compared to 5.2% in standard surgical dressings (p=0.04).  
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Meberg et al21 recruited 2441 new born infants on an obstetrics ward with the mothers 
providing consent. Infants were randomised on a 1:1 ratio to either having the umbilical 
cord stump covered with a DACC coated dressing or daily cleansing with 0.5% chlorhexidine 
in 70% ethanol solution. Primary outcome was the incidence of new born infection including 
conjunctivitis, pyoderma, paronychia and omphalitis. Infants were followed up for up to 6 
weeks. Overall 377 (15.4%) cases of infection in general were reported. There was no 
statistical significance in infection rates between the DACC dressing group and the 0.5% 
chlorhexidine in 70% ethanol solution group (16.3% and 14.6% respectively, p>0.05). 
 
Choi et al14 presented a case series of seven patients in whom skin grafts were fixed with 
the use of a DACC-coated wound contact layer and tie-over dressing. All wounds were post-
excision of lesion in theatre, and so were clean surgical wounds at the point of application 
of DACC coated dressings. No wounds experienced infection in this small case series. 
 
Synthesis of results 
No meta-analysis of trial data was possible for the included studies, due to differences in 
trial methodology and outcome measures. There were only two trials27 28 with similar 
enough outcome measures and methods to consider a meta-analysis, however the 2014 
Stanirowski28 trial used the observed effect size to influence the power calculation of the 
2016 study27. It was felt by the authors that a meta-analysis of this data would add nothing 
further to the findings present in the larger scale RCT. 
 
Discussion 
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Summary and limitations of evidence for DACC in chronic wounds 
The evidence examining DACC dressings in chronic wound management is low level (small 
to medium case studies). In general, the outcomes from these studies is positive however 
many of the outcome measures were highly subjective. The only randomised controlled 
evidence in chronic wounds was targeted at the bacterial load within the wound and did not 
include objective clinical outcomes20. This study had a very limited sample size (n=13) and 
compared dressings in the same wound bed introducing the possibility of contamination. 
Reports to date are generally encouraging, but there is clearly a need for rigorously 
designed trials with adequate sample sizes to produce the level 1 or 2 evidence needed to 
properly determine the efficacy of this technology in chronic wound management.  
 
Summary and limitations of evidence for DACC as prophylaxis against wound infection  
The evidence to support DACC dressings use as prophylaxis for SSI in clean surgical wounds 
is, in theory, of higher quality in that it is based on randomised trials, though the trials 
reviewed were generally at high risk of bias. Prospective work by Stanirowski et al28 and 
earlier work by Meberg21 did not show a statistically significant difference in infection rates 
when DACC dressings were used. The design of both studies was sub-optimal including poor 
treatment allocation and concealment methods, and lack of blinding of participants or 
investigators.  
 
The full RCT by Stanirowski et al27 reported a significant reduction in the SSI rates in 
caesarean section patients receiving DACC compared to standard surgical dressings. 
However this RCT had significant weaknesses in trial design. There was no allocation 
concealment and nor was the study truly randomised, since consecutive patients were 
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simply alternated between study arms. Primary outcome was reported as SSI according to 
centre for disease control (CDC) definitions of superficial or deep SSI. However, the follow 
up period was only 14 days long, which is insufficient to capture all SSI according to the CDC 
definition which includes wound infection up to 30 days post procedure29. Trial methods 
were improved for the larger study in comparison to the pilot, in that the wound 
assessments for the larger trial were performed by investigators blinded to dressing type.  
This may account for the improvement in the SSI rate in the control group, which was 9.8% 
in the pilot but reduced to only 5.2% in the full RCT despite identical surgical methods.   
 
This purpose of this review, as outlined above, was to examine the evidence for the clinical 
use of DACC-coated dressings. Only one article27 published data on the cost effectiveness of 
the intervention, which was not taken into consideration in this review. This is due to a 
significant disparity between the cost of the intervention reported in the article and the 
actual cost of the intervention on the UK market (mean cost of Leukomed® Sorbact® 
dressing in the trial reported as €2.80; mean cost of Leukomed® Sorbact® dressings in the 
UK (as of Aug 2015) £8.06), making any cost analysis difficult to apply to the reviewer’s 
patient cohort. 
 
All of the available evidence does favour DACC coated dressings over conventional, non-
coated dressings, and in some cases over more traditional silver coated dressings. This 
provides further evidence that more research into this field of study would be beneficial. 
 
Limitations of the review 
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During the search process, at least one article was identified that was classed as a review of 
the evidence30. This was a non-systematic collection of current evidence written on behalf 
of the product manufacturer that provided a number of references that were included in 
the search (additional records identified through other sources, figure 2). Our review, in 
general, agrees with their findings, however the systematic nature of our review, and the 
stricter inclusion criteria, meant a much smaller number of studies were included. The 
product literature did include a large amount of unpublished data presented at conferences, 
that was not included in our review, raising the possibility that the conclusions of our review 
have been impacted by this data not being made available. 
This review did include a large number of low-level studies (small case studies). This was due 
to a relative paucity of good quality scientific studies into the effects of DACC-coated 
dressings in comparison to currently accepted standard practice.  
 
Conclusion 
DACC coating of dressings shows promise in both the prevention and treatment of wound 
infections, though published results are not as yet sufficient to firmly conclude either the 
clinical or cost effectiveness of its use, and therefore directly impact day-to-day clinical 
practice. However, the available evidence that is presented is in support of DACC coated 
dressings, and such promise does allow for the undertaking of further high quality research 
into their clinical and cost effectiveness. 
 
Funding 
No external funding was obtained for this review. 
Potential Conflict of interests 
 13 
All authors report no potential conflict of interests relevant to this article. 
 
 
  
 14 
References 
1. Posnett J, Franks PJ. The burden of chronic wounds in the UK. Nurs Times 2008;104(3):44-
5. [published Online First: 2008/02/26] 
2. Leaper D, Burman-Roy S, Palanca A, et al. Prevention and treatment of surgical site 
infection: summary of NICE guidance. BMJ 2008;337:a1924. [published Online First: 
2008/10/30] 
3. Adams-Howell P, Bhabra M, Enright M, et al. Under the Knife Report: Taking a zero 
tolerance approach to preventable surgical site infections in UK hospitals 
http://www.carefusion.co.uk/.../infection.../IP_Under-the-knife_CE_EN.pdf2011 
[accessed 7th September 2016. 
4. Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection - a European perspective of 
incidence and economic burden. International Wound Journal 2004;1(4):247-73. 
5. Ljungh A, Wadström T. Growth conditions influence expression of cell surface 
hydrophobicity of staphylococci and other infection pathogens. Microbiol Immunol 
1995;39:753-57. 
6. Ljungh A, Yanagisawa N, Wadström T. Using the principle of hydrophobic interaction to 
bind and remove wound bacteria. Journal of Wound Care 2006;15:175-80. doi: 
10.12968/jowc.2006.15.4.26901 
7. von Hallern B, Lang F. Has Cutisorb® Sorbact® proved its practical value as an 
antimicrobial dressing? Medizin & Praxis Spezial - Infected wounds, 2005. 
8. Probst A, Norris R, Cutting K. Cutimed® Sorbact® Made easy. Wounds International 
2012;3:1-6. 
9. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6(7):e1000097. doi: 
10.1371/journal.pmed.1000097 
10. Higgins J, Altman D. Assessing risk of bias in included studies. Cochrane Handbooks for 
systematic reviews of intervention: Chichester, UK: Wiley-Blackwell, 2011:187 -242. 
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized 
clinical trials: is blinding necessary? Controlled clinical trials 1996;17(1):1-12. 
[published Online First: 1996/02/01] 
12. Bruce Z. Using Cutimed® Sorbact® hydroactive on chronic infected wounds. Wounds UK 
2012;8:119-29. 
13. Bullough L, Little G, Hodson J, et al. The use of DACC-coated dressings for the treatment 
of infected, complex abdominal wounds. Wounds UK 2012;8:102-09. 
14. Choi JS, Lee JH, Kim SM, et al. Hydrogel-impregnated dressings for graft fixation: a case 
series. J Wound Care 2015;24(7):326-8. doi: 10.12968/jowc.2015.24.7.326 
[published Online First: 2015/07/23] 
15. Derbyshire A. Innovative solutions to daily challenges: Cutimed®Sorbact® follow-up case 
studies. British journal of community nursing 2010;Suppl:S38, S40-5. 
16. Gentili V, Gianesini S, Balboni PG, et al. Panbacterial real-time PCR to evaluate bacterial 
burden in chronic wounds treated with Cutimed™ Sorbact™. European Journal of 
Clinical Microbiology and Infectious Diseases 2012;31:1523-29. doi: 10.1007/s10096-
011-1473-x 
17. Hampton S. An evaluation of the efficacy of Cutimed® Sorbact® in different types of non-
healing wounds. Wounds UK 2007;3:113-19. 
 15 
18. Haycocks S, Chadwick P. Use of DACC- coated dressings in diabetic foot ulcers: A case 
series. The Diabetic Foot Journal 2011;14(3):133-37. 
19. Kammerlander G, Locher E, Suess-Burghart A, et al. An investigation of Cutimed® 
Sorbact® as an antimicrobial alternative in wound management. Wounds UK 
2008;4:10-18. 
20. Kleintjes WG, Schoeman D, Collier L. A pilot study of Cutimed® Sorbact® versus 
ACTICOAT™ versus Silverlon® for the treatment of burn wounds in a South African 
adult burn unit. Wound healing South Africa 2015;8(2):22-29. 
21. Meberg A, Schøyen R. Hydrophobic Material in Routine Umbilical Cord Care and 
Prevention of Infections in Newborn Infants. Scandanavian Journal of Infection 
Diseases 1990;22:729-33. 
22. Mosti G, Magliaro a, Mattaliano V, et al. Comparative study of two antimicrobial 
dressings in infected leg ulcers: a pilot study. Journal of wound care 2015;24:4-9. doi: 
10.12968/jowc.2015.24.3.121 
23. Pirie G, Duguid K, Timmons J. Cutimed® Sorbact® gel: A new infection management 
dressing. Wounds UK 2009;5:74-78. 
24. Powell G. Evaluating Cutimed Sorbact: using a case study approach. The British journal of 
nursing 2009;18:S30, S32-S36. 
25. Sibbald G. The Effectiveness Of A New Antimicrobial Dressing With Microbinding Action 
For The Management Of Chronic Wounds. Wound Care Canada 2012;10(3):20-22. 
26. Skinner R, Hampton S. The diabetic foot: managing infection using Cutimed Sorbact 
dressings. The British journal of nursing 2010;19:S30, S32-S36. 
27. Stanirowski PJ, Bizoń M, Cendrowski K, et al. Randomized Controlled Trial Evaluating 
Dialkylcarbamoyl Chloride Impregnated Dressings for the Prevention of Surgical Site 
Infections in Adult Women Undergoing Cesarean Section. Surgical infections 
2016;17:427-35. doi: 10.1089/sur.2015.223 
28. Stanirowski PJ, Kociszewska A, Cendrowski K, et al. Dialkylcarbamoyl chloride-
impregnated dressing for the prevention of surgical site infection in women 
undergoing cesarean section : a pilot study. Clinical research 2014:1-7. doi: 
10.5114/aoms.2015.47654 
29. Bruce J, Russell E, Mollison J, et al. The measurement and monitoring of surgical adverse 
events. Health Technology Assessment 2001;5:194. doi: 10.3310/hta5220 
30. Cutting K, McGuire J. In vitro and clinical experience of Cutimed Sorbact: the evidence 
base. J Wound Care 2015;24(5 Suppl):S6-30. doi: 10.12968/jowc.2015.24.Sup5a.S6 
[published Online First: 2015/06/17] 
 
  
 16 
Figure 1. Photographs of Leukomed® Sorbact®, a commercially available DACC-coated 
dressing, against a white background. The coloured nature of the wound contact layer is 
demonstrated. 
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Table 1. Search strategies 
 
Resource Searched: Embase 1974 to 2016 September 13 and Ovid MEDLINE 1946 to Present (All mapped to 
subject headings) 
Search Terms Results 
1 Dialkylcarbamoylchloride.mp 3 
2 Dialkylcarbamoyl chloride.mp 5 
3 Dialkyl carbamoyl chloride.mp 13 
4 DACC.mp 1063 
5 leukomed.mp 5 
6 cutimed.mp 45 
7 sorbact.mp 58 
8 hydrophob*.mp 240177 
9 dressing.mp 38498 
10 8 and 9 179 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 10 1281 
12 infect*.mp 4099272 
13 wound*.mp 619850 
14 surg*.mp 4422074 
15 ulcer*.mp 538117 
16 12 or 13 or 14 or 15 8790031 
17 11 and 16 259 
18 limit 17 to human 158 
19 limit 18 to English language 150 
Resource Searched: CINAHL via EBSCOHost 
Search Terms Results 
S1 Dialkylcarbamoylchloride OR Dialkyl carbamoyl chloride OR Dialkylcarbamoyl 
chloride OR DACC 
54 
S2 leukomed OR cutimed OR sorbact 21 
S3 hydrophob* AND dressing* 16 
S4 S1 OR S2 OR S3 85 
S5 infect* OR wound* 316031 
S6 S4 AND S5 (Limits: English Language) 40 
Resource Searched: CENTRAL via Cochrane Collaboration 
Search Terms Results 
1 Dialkylcarbamoylchloride 0 
2 Dialkyl carbamoyl chloride 1 
3 Dialkylcarbamoyl chloride 0 
4 DACC 39 
5 leukomed OR cutimed OR sorbact 14 
6 hydrophob* 374 
7 dressing 3069 
8 #6 and #7 6 
9 #1 or #2 or #3 or #4 or #5 or #8 58 
10 wound* 23551 
11 infect* 87186 
12 #10 or #11 101554 
13 #9 and #12 19 
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Table 2. Summary of included studies 
 
REFERENCE METHODS PARTICIPANTS INTERVENTIONS OUTCOMES PRIMARY FINDINGS 
STANIROWSKI 201627 Single blinded, 
randomised control trial 
543 Females >18 
undergoing planned or 
emergency caesarean 
section 
Randomised to either DACC 
coated post-operative 
dressing or standard 
surgical dressing 
Superficial or deep SSI 
within the first 14 days 
after CS (defined as per 
CDC) 
SSI rates of 1.8% in 
DACC vs 5.2% in 
control (p=0.04) 
STANIROWSKI 201428 Single blinded, 
randomised, controlled 
pilot study 
142 Females >18 years 
undergoing planned or 
emergency caesarean 
section  
Randomised to either DACC 
coated post-operative 
dressing or standard 
surgical dressing 
Superficial or deep SSI 
within the first 14 days 
after CS (defined as per 
CDC) 
SSI rates of 2.8% in 
DACC vs 9.8% in 
control (p=0.08) 
CHOI 201514 Case series 7 patients (4 male) 
requiring skin graft of 
varying thickness on clean 
surgical wounds 
Skin graft dressed with 
DACC coated dressing and 
tie-over dressing for 5 days 
Wounds checked for 
infection at 5 days, 14 
days and 30 days post-
procedure 
No wounds 
experienced infection 
BULLOUGH 201213 Case series 4 patients with complex 
open abdominal wounds 
DACC coated dressings and 
swabs used as a wound 
contact layer for the 
duration of treatment 
Wound infection 
recurrence; wound 
dimension; wound 
healing; pain during 
dressing changes; exudate 
and odour 
3 of 4 wounds 
healed, and all signs 
of wound infection 
had resolved by day 
14 of treatment.  
GENTILI 201216 Non-comparative, double 
blind, pilot study 
19 consecutive patients 
with chronic lower limb 
ulcers 
Wounds were treated with 
a 0.9% NaCl saline solution 
rinse, surgical debridement 
and application of DACC 
dressing. The study was 
performed during a 4-week 
period. 
Evaluation of wound 
condition, quality of life, 
bacterial load 
66% of wounds 
reduced in size. 
Reduction of 
bacterial load in all 
cases. 
PIRIE 200923 Case series 3 patients (one male) with 
chronic non-healing 
wounds referred to tissue 
viability services 
DACC coated dressing used 
as a primary wound contact 
layer in combination with 
other dressings and 
therapies 
Wound healing, evidence 
of infection, wound size, 
exudate levels 
All showed clinical 
improvement 
(reduced wound size 
and slough). 
KAMMERLANDER 200819 Non-randomised multi-
centre evaluation 
116 patients (62 male) 
presenting to one of four 
European hospitals with a 
Patients were treated with 
Cutimed® Sorbact® as part 
of their therapeutic regime 
study questioned whether 
it could reduce 
inflammation; reduce 
81% of wounds were 
successfully treated 
for infection. 21% of 
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wound deemed to be at 
high risk of infection 
infection; improve wound 
healing; be patient 
tolerable 
wounds healed 
completely. 
HAMPTON 200717 Case Series 21 patients (7 male) with 
non-healing (>3 months) 
wounds that were not 
clinically infected 
Patients were treated with 
Cutimed® Sorbact® as part 
of their therapeutic regime 
Inflammation, exudate, 
malodour, wound size, 
pain 
60% of wounds 
healed, 100% had 
reduced exudate 
levels and 58% had 
reduced wound 
odour 
MOSTI 201522 Randomised, 
comparative, single 
centre study 
40 patients >18 with 
critically colonised or 
locally infected vascular 
ulcers of duration ≥6 
months 
Patients randomised to 
Silver containing hydrofibre 
dressing or DACC-coated 
dressing 
Primary: Ulcer bacterial 
load 
Reduction of 
bacterial load of 
73.1% DACC vs 41.6% 
Silver (P<0000.1) 
SKINNER 201026 Case Series 4 patients (3 male) with 
diabetic foot ulcers 
Patients were treated with 
Cutimed® Sorbact® as part 
of their therapeutic regime 
Bacterial colonisation, 
infection, wound healing 
One wound healed 
completely. ¾ 
progressed towards 
healing. 
POWELL 200924 Case series 6 patients (3 male) with a 
variety of wounds showing 
clinical infection or delayed 
healing 
Cutimed® Sorbact® used as a 
wound contact layer for 2-8 
weeks 
Inflammation, exudate, 
odour, wound healing 
100% of wounds 
were reduced in size, 
exudate and odour. 
80% wounds healed 
completely 
MEBERG 199021 Randomised control trial 2441 newborn infants Patients alternately 
allocated to umbilical cord 
stump dressing with either 
(i) DACC coated dressing or 
(ii) daily cleansing with 
0.5% chlorhexidine in 70% 
alcohol 
Infection in the newborn 
(conjunctivitis, pyoderma, 
paronychia and 
omphalitis) 
No significant 
difference in either to 
overall rate of 
infection or in 
omphalitis 
BRUCE 201212 Multi-centre evaluation 13 patients (7 male) with 
chronic wounds of varying 
aetiology with signs of 
infection 
Treated with DACC-coated 
dressings for 28 days or 
until signs of infection had 
resolved 
Erythema, pain, heat, 
oedema, odour, exudate 
86% reduction in 
infection; reduction 
in wound size in 79% 
of wounds 
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DERBYSHIRE 201015 Case Series 3 patients with wounds of 
duration > 4 years.  
Patients were treated with 
Cutimed® Sorbact® as part 
of their therapeutic regime. 
Wound size, wound 
healing, resource use, 
pain, exudate levels 
All wounds were 
cleaner, dryer, and 
required less nursing 
care/dressing 
changes 
KLEINTJES 201520 Prospective pilot study 13 patients >16 years of 
age with burn wounds 
large enough to 
accommodate three 
different trial dressings 
Burns were dressed with 
DACC coated dressings, 
Acticoat® and Silverlon®, 
three dressings to the same 
burn 
Wound swab MC&S, 
visual inspection of 
wounds 
Wound areas dressed 
with DACC-coated 
dressings appeared 
subjectively cleaner 
and has less bacterial 
growth on MC&S 
SIBBALD 201225 Case Series 14 patients with lower 
limb ulceration (8 diabetic 
foot ulcers, 6 venous leg 
ulcers) 
Ulcers dressed 3 times a 
week for 4 weeks with a 
DACC-coated dressing 
Superficial infection (as 
assessed by NERDS or 
STONEES criteria), total 
ulcer surface area, pain 
Reduction in total 
average surface area 
from 1.74cm2 to 
1.15cm2 (p=0.337). 
No significant 
difference in 
superficial or deep 
infection rate. 
HAYCOCKS 201118 Case Series 19 patients (13 male) with 
diabetic foot ulceration up 
to the age of 80 years, with 
a total of 29 separate 
wounds studied 
All wounds treated with a 
DACC-coated dressing as a 
wound contact layer for 4 
weeks 
Infection, healing, patient 
and clinician assessment 
By study end, all 29 
wounds had reduced 
signs of infection. 
69% of wounds had 
reduced in size and 
27.6% of wounds had 
healed. 
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Figure 2. PRISMA Flow Diagram 
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(n = 223) 
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Additional records identified 
through other sources 
(n = 29) 
Records screened by title and/or abstract 
(n = 252) Records excluded 
(n = 218) 
Full-text articles 
assessed for eligibility 
(n = 34) 
Full-text articles excluded 
(n = 17) 
Study Protocol (n = 1) 
DACC with NPWT (n = 1) 
In vitro study (n = 6) 
Case study with n<3 (n = 1) 
Infection or healing not measured as an 
outcome (n = 1) 
Patient cohort interdigital fungal infection 
(n = 1) 
Commercial product review or review of 
evidence (n = 3) 
Results already published as part of a 
larger series (n = 1) 
Unable to ascertain which subjects given 
DACC treatement (n = 1) 
Unable to obtain full text article (n = 1) 
 
 
Studies included in 
qualitative synthesis 
(n = 17) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
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Table 3: Risk of bias assessment in the included randomised studies 
 
Study Random 
Sequence 
Generation 
(selection 
bias) 
Allocation 
Concealment 
(selection bias) 
Blinding 
(performance bias 
and detection bias) 
Incomplete outcome 
data (attrition bias) 
Selective reporting 
(reporting bias) 
Other Bias JADAD 
score 
Stanirowski 
201428 
High High High Low Low Low 2 
Stanirowski 
201627 
High High High Low Low Low 2 
Meberg 
199021 
High High High Low Low Low 2 
Mosti 
201522 
Low Low High Low Low Low 3 
 
Table 4: Risk of bias assessment for the included cohort study 
 
Study Representativeness 
of the exposed 
cohort 
Ascertainment of 
exposure 
Demonstration that outcome 
of interest was not present at 
start of study 
Comparability of cases 
and controls on the 
basis of the design or 
analysis 
Assessment of 
outcome 
Adequacy of 
follow up of 
cohorts 
Were co-
interventions 
similar between 
groups 
Kleintjes 
(2015)20 
Definitely yes  
(low risk of bias) 
Definitely yes 
(low risk of bias) 
Probably yes Definitely yes 
(low risk of bias) 
Definitely yes 
(low risk of bias) 
Definitely yes 
(low risk of bias) 
Definitely yes 
(low risk of bias) 
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